Comprehensive Management Plan: Mrs. Sarah Chen

Stress Urinary Incontinence with Urethral Hypermobility and Pelvic Floor Muscle Dysfunction

PART 1: DIAGNOSTIC SYNTHESIS AND PROBLEM LIST

Primary Diagnosis

• Positive cough stress test (immediate leakage, moderate stream)
• Cotton swab test: straining angle 45° (positive >30° = urethral hypermobility)
• Leakage with jumping jacks at 3 repetitions
• Classic precipitants: coughing, sneezing, laughing, lifting, brisk walking, stairs

Contributing Factors (Problem List)

PART 2: LEARNING GOALS (Patient-Centred)

Goal 1 - PRIORITY: Correct PFM Identification and Isolation

Goal 2 - HIGH PRIORITY: Understand the "Knack" Maneuver

Goal 3 - HIGH PRIORITY: Understand Her Condition (Anatomy and Pathophysiology)

Goal 4 - MEDIUM PRIORITY: Master Progressive PFMT Program

Goal 5 - MEDIUM PRIORITY: Lifestyle Modification for Bladder Health

Goal 6 - MEDIUM PRIORITY: Resume Physical Activity Safely

Goal 7 - LOWER PRIORITY (Ongoing): Address Psychosocial Impact

PART 3: PRIORITISED COMPREHENSIVE MANAGEMENT PLAN

TIER 1 - IMMEDIATE (Weeks 1-2): Foundation

1A. Patient Education Session (60 min)

• Pelvic anatomy using diagrams: levator ani, pubourethral ligament, urethra
• Explanation of Integral Theory in lay language: "The hammock under your bladder has become lax. When pressure spikes - cough, sneeze, laugh - the urethra can't close fast enough."
• Explain that her previous Kegels were counterproductive (bear-down = pushing down, not lifting up)
• Reassurance: SUI is very treatable conservatively in women with mild-moderate severity
• Provide written information + recommend validated patient resource (e.g., Continence Foundation of Australia or ICS leaflets)

1B. Bladder Diary

• 3-day frequency/volume diary
• Record: time of void, volume (measured cup), leakage episodes, precipitant, fluid type and amount
• Goals: establish baseline, identify caffeine/fluid patterns, empower self-monitoring (Smith and Tanagho's General Urology - behavioral therapy begins with bladder diary, p. 517)

1C. PFM Motor Control Re-Education (Session 1-2)

• Position: supine with hips/knees flexed (reduces gluteal substitution)
• Internal digital palpation guidance: distinguish lift/squeeze vs. bear-down
• Visual feedback: mirror observation of perineum if acceptable
• Verbal cues: "lift as if stopping the flow of urine AND passing wind at the same time"
• Confirm: no abdominal doming, no gluteal contraction, no breath-holding
• Teach diaphragmatic breathing concurrent with PFM contraction (avoid Valsalva)

1D. Teach the Knack (Immediate Functional Benefit)

• Pre-contract PFM 1-2 seconds BEFORE any known pressure event (cough, sneeze, lift)
• Practice: ask to cough while clinician checks perineum for correct pre-contraction
• Apply to: lifting grandchildren, stepping off kerb, climbing stairs
• This gives immediate reduction in leakage episodes and restores confidence

TIER 2 - EARLY (Weeks 2-8): Active Rehabilitation

2A. Supervised PFMT Protocol (evidence-based, ≥12 weeks)

• 10× slow holds at maximum comfortable effort, hold 3-4 seconds, relax 8 seconds
• 10× quick flick contractions (1 second on/off)
• 3 sets/day, positions: lying → sitting → standing (progress as control improves)
• Frequency: daily; supervised sessions 1×/week initially

• Increase hold time to 6-8 seconds
• 10× holds + 10× quick flicks, 3 sets
• Begin functional integration: contract during light activity (walking, standing from chair)
• Supervised sessions every 2 weeks

• 10-second holds × 10 repetitions, 3 sets/day
• Integrate with higher-impact activities: stair climbing, brisk walking
• Reduce to 1×/month supervised (maintenance)

2B. Biofeedback (if progress is slow at Week 4 review)

• Adjunct tool if she remains unable to isolate PFMs correctly
• Surface EMG or pressure biofeedback probe provides real-time visual confirmation
• Particularly useful given her bear-down pattern at baseline

2C. Fluid and Lifestyle Management

• Target fluid: 1.5-2.0L/day, evenly distributed (not front-loaded in morning)
• Reduce caffeine: switch one cup of coffee to decaf/herbal tea
• Avoid bladder irritants: carbonated drinks, artificial sweeteners, citrus excess
• Timing strategy: void every 3-3.5 hours rather than "just in case" every 2 hours (extend slightly to re-train bladder capacity)
• Bowel regularity: adequate fibre, hydration, avoid straining at stool (all increase intra-abdominal pressure)

2D. Address Vaginal Atrophy

• Refer to GP/gynaecologist for assessment of local vaginal oestrogen therapy
• WHI and HERS data show systemic HRT worsens SUI; however, local (vaginal) oestrogen may improve urethral mucosal coaptation and urgency/frequency symptoms in the short term (Berek & Novak's Gynecology, block8)
• Local oestrogen is not systemically absorbed at significant levels and is considered safe in most postmenopausal women without contraindications

2E. Weight Management (Gradual)

• BMI 29 - not severely obese, but even 5-10% weight reduction reduces intra-abdominal pressure on bladder
• Refer to dietitian for low-glycaemic Mediterranean-style dietary advice
• Frame around energy for grandchildren rather than weight loss per se (aligns with her goals)

2F. NSAID Review

• Current: ibuprofen for knee OA
• Ibuprofen can increase urethral smooth muscle relaxation marginally; more importantly, long-term NSAID use has renal effects affecting fluid balance
• Discuss with GP: consider topical diclofenac gel for knee pain to reduce systemic exposure
• Encourage hydrotherapy or aquatic exercise as OA-friendly alternative (reduces impact on knees AND assists weight management)

TIER 3 - MID-TERM (Months 3-6): Reassessment and Escalation Decision

3A. Re-assessment at 12 Weeks

• Modified Oxford Scale (target ≥ Grade 3)
• Cough stress test (target: no leakage with single cough standing)
• Bladder diary: frequency, episode count
• Re-administer UDI-6 and IIQ-7 (target: ≥30% reduction in scores)
• Patient goal attainment: walking with friends? Attending grandchildren's activities?

3B. Pharmacological Option (if PFMT inadequate)

• Duloxetine (SNRI): increases efferent output at Onuf's nucleus → increases urethral smooth muscle tone → reduces SUI episodes. Effective in mild-moderate SUI; approved in Europe (not USA). (Campbell-Walsh Urology, block60 - Onuf nucleus mechanism)
• Side effects: nausea, fatigue, insomnia, dizziness - may preclude as first-line
• Offer as adjunct to ongoing PFMT if partial response at 12 weeks
• Not: systemic HRT (worsens SUI per WHI and HERS data), anticholinergics (no role in pure SUI)
• Note: Lisinopril (current medication) does not directly impact SUI; however, ACE inhibitors can cause chronic cough - confirm whether her "cough" precipitant is partly ACE inhibitor induced; if so, discuss with GP regarding switch to ARB (losartan/candesartan)

TIER 4 - SURGICAL REFERRAL CRITERIA (if conservative management fails at 6 months)

• Inadequate response after ≥3-6 months of supervised PFMT
• Significant quality-of-life impairment persists (IIQ-7 remains elevated)
• Patient desires definitive treatment

• Mid-urethral sling (MUS): retropubic (TVT) or transobturator (TOT) approach - current gold standard for SUI with urethral hypermobility; continence rates ~85-90% at 5 years (Berek & Novak's Gynecology, Integral Theory - Petros & Ulmsten, block7)
• Urethral bulking agents: less effective, useful for frail patients or those who decline sling
• Note: Surgery is not indicated at this stage - she has not yet received adequate supervised conservative management

PART 4: PSYCHOSOCIAL AND FUNCTIONAL GOALS

• Consider referral for brief psychological support (CBT or acceptance-based therapy) if avoidance and social withdrawal persist despite physical improvement
• Husband involvement: encourage him to accompany her to one education session - his support is already present (documented as supportive), formalise this

PART 5: MEDICATION CONSIDERATIONS SUMMARY

PART 6: OUTCOME MEASURES AND REVIEW SCHEDULE

SUMMARY: PRIORITY ORDER FOR CLINICAL ACTION

1. Immediately: Correct bear-down pattern → teach true PFM contraction + Knack
2. Week 1: Start bladder diary + patient education about SUI pathophysiology
3. Weeks 1-12: Supervised PFMT program (min. 12 weeks, progressive loading)
4. Week 2: Fluid/caffeine management; discuss local vaginal oestrogen with GP; review Lisinopril cough
5. Month 3: Reassess; consider duloxetine if partial response
6. Month 6: Consider urogynaecology referral if PFMT-resistant SUI persists

• Campbell-Walsh-Wein Urology, Treatment of SUI + Behavioral Conservative Treatments (blocks 62, 66)
• Berek & Novak's Gynecology, Stress Urinary Incontinence: Pathogenesis + Medications (blocks 7, 8)
• Smith and Tanagho's General Urology, 19th Ed., Behavioral Therapy (block 5)
• Moris L et al. (2025). Prevalence, Diagnosis, and Management of SUI in Women. Eur Urol [PMID: 39848866]
• Mantilla Toloza SC et al. (2024). Pelvic floor training to prevent SUI: A systematic review. Actas Urol Esp [PMID: 38556125]

Student Learning Objectives

• I want to learn how to identify and assess stress urinary incontinence (SUI) in a postmenopausal woman, including the use of clinical tools such as the Modified Oxford Scale, cough stress test, and cotton swab test to confirm urethral hypermobility and pelvic floor muscle dysfunction.
• I want to learn the underlying pathophysiology of SUI - specifically how hormonal changes after menopause, obstetric history (forceps delivery), and connective tissue laxity contribute to urethral hypermobility and loss of the pelvic floor "hammock" support mechanism.
• I want to learn how to design and progress a supervised pelvic floor muscle training (PFMT) program for a patient with an incorrect bear-down pattern, including how to teach correct PFM isolation, the Knack maneuver, and a phased exercise progression over 12 weeks.
• I want to learn how to select and justify appropriate first-line conservative management strategies for SUI - including PFMT, bladder diary, fluid and caffeine modification, local vaginal oestrogen, and weight management - while recognising when to escalate to pharmacological or surgical options.
• I want to learn how to address the psychosocial and functional impact of SUI using validated outcome measures (UDI-6, IIQ-7), set patient-centred goals aligned with the patient's values and daily life, and integrate a biopsychosocial approach into the overall management plan.